BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Open accessPublished version of a preprint
The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited success because of activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback node, represents an effective approach to treat KRAS-driven cancers. We report the discovery of a highly potent, selective, and orally bioavailable small-molecule SOS1 inhibitor, BI-3406, that binds to the catalytic domain of SOS1, thereby preventing the interaction with KRAS. BI-3406 reduces formation of GTP-loaded RAS and limits cellular proliferation of a broad range of KRAS-driven cancers. Importantly, BI-3406 attenuates feedback reactivation induced by MEK inhibitors and thereby enhances sensitivity of KRAS-dependent cancers to MEK inhibition. Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven tumors. Significance: To date, there are no effective targeted pan-KRAS therapies. In-depth characterization of BI-3406 activity and identification of MEK inhibitors as effective combination partners provide an attractive therapeutic concept for the majority of KRAS-mutant cancers, including those fueled by the most prevalent mutant KRAS oncoproteins, G12D, G12V, G12C, and G13D. See related commentary by Zhao et al., p. 17. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In heterozygous KRAS mutant tumor cells, RAS signaling can be supplemented and cross-regulated by RTK-WT RAS signaling.”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because KRAS G12C inhibitors preferentially target the GDP-bound conformation, combined inhibition of SOS1 may enhance therapeutic efficacy by increasing the fraction of inhibitor-accessible KRAS [60].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As evidenced by reports of small molecules targeting the RAS GEF SOS1, inhibition of GEF activity would thus arrest the given GTPase signaling pathways, constituting a promising target for small-molecule therapeutic development (11, 12).”
From RHO to the DOCK for GDP disembarking: Structural insights into the DOCK GTPase nucleotide exchange factors (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SHP2 and SOS1 function upstream of KRAS and play central roles in receptor tyrosine kinase-mediated RAS activation [16,60].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [60]
The cited source says what the claim attributes to it.
In the citing paper
“In preclinical studies, BI-3406 decreased cellular proliferation in a range of KRAS-mutant NSCLC, PDAC and colon cancer cell lines137.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [137]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Promising early results 87 from clinical trials with the two inhibitors AMG 510 and MRTX849, both targeting the 88 KRAS G12C mutant allele covalently and specifically (12,13), have been reported.”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 2×
“Promising early results 87 from clinical trials with the two inhibitors AMG 510 and MRTX849, both targeting the 88 KRAS G12C mutant allele covalently and specifically (12,13), have been reported.”
BackgroundEgan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., & Weinberg, R. A. (1993) · Nature · doi:10.1038/363045a0 · Cited by 1,215
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · cited 8×
“This suggests that BI-3406 and SHP099 possess a partially overlapping yet distinct profile across KRAS-mutated cell lines, with BI-3406 being more broadly active in 3-”
BackgroundInfluentialEssential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Wood, L. D., Canto, M. I., Jaffee, E. M., & Simeone, D. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.056 · Cited by 865
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534
Self-citationRole of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
“bioavailable inhibitor of the SOS1-KRAS interaction, and it only inhibits SOS1 and not SOS2 [80].”
Background
Metadata
- Authors
- Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., Rumpel, K., Botesteanu, D.-A., Ettmayer, P., Gerstberger, T., Kofink, C., Wunberg, T., Zoephel, A., Fu, S.-C., Teh, J. L., Böttcher, J., Pototschnig, N., Schachinger, F., Schipany, K., Lieb, S., Vellano, C. P., O'Connell, J. C., Mendes, R. L., Moll, J., Petronczki, M., Heffernan, T. P., Pearson, M., McConnell, D. B., & Kraut, N.
- Affiliations
- Boehringer Ingelheim (Austria) (AT)
- 1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
- The University of Texas MD Anderson Cancer Center (US)
- 4Forma Therapeutics, Watertown, Massachusetts.
- Forma Therapeutics (United States) (US)
- ORCID
- Hofmann, Marco H.
- Gmachl, Michael
- Gerlach, Daniel
- Marszalek, Joseph R.
- Sanderson, Michael P.
- Kessler, Dirk
- Trapani, Francesca
- Rumpel, Klaus
- Botesteanu, Dana-Adriana
- Ettmayer, Peter
- Gerstberger, Thomas
- Kofink, Christiane
- Wunberg, Tobias
- Zoephel, Andreas
- Teh, Jessica L.
- Böttcher, Jark
- Schachinger, Franziska
- Vellano, Christopher P.
- Petronczki, Mark
- Heffernan, Timothy P.
- Pearson, Mark
- McConnell, Darryl B.
- Kraut, Norbert
- Venue
- Cancer Discovery
- Published
- 2021-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 142-157
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7892644
- OpenAlex
- W3077914340
- Cited by
- 444
- References
- 56
- Citations by year
- 2026: 55 · 2025: 76 · 2024: 98 · 2023: 82 · 2022: 70 · 2021: 59
- FWCI
- 17.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Funders
- Boehringer Ingelheim and the Austrian Research Promotion Agency (854341, 861507, 867897, 874517)
- the MDACC Science Park NGS Core (RP170002)
- NCI (#CA16672)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- SOS1 inhibitor, KRAS, MEK inhibition, Raf/MEK/ERK pathway, KRAS-driven cancers, KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D, combination therapy, small-molecule kinase inhibitors, pancreatic cancer, colorectal cancer, non-small cell lung cancer
- MeSH terms
- Humans, Lung Neoplasms, Mutation, Nucleotides, Proto-Oncogene Proteins p21(ras), Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0142
- The paper
- Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., Rumpel, K., Botesteanu, D.-A., Ettmayer, P., Gerstberger, T., Kofink, C., Wunberg, T., Zoephel, A., Fu, S.-C., Teh, J. L., . . . Kraut, N. (2021). BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.